Intrinsiqq
Cardio Diagnostics Holdings Inc. logo

Cardio Diagnostics Holdings Inc. Quality Score

CDIO

⊜ Compare
Quality30

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.6x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-0.8x

Negative FCF, no valuation support

Revenue Growth
100/100
97.5%

Above 10% CAGR, strong compounder

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
2775.4%

Heavy dilution above 5%

Margin Trend
100/100
+434093.6pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$302250

Positive debt with no FCF to service it

2022
$0.00
$0.00
2023
$0.00
$887028
2024
$0.00
$663099
2025
$0.00
$425829
TTM
$0.00
$302250
CashDebt
Return on Capital
0/100
-61.8%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Cardio Diagnostics Holdings (CDIO) quality: score, margins and returns

Cardio Diagnostics Holdings (CDIO) scores 30/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 6 metrics each scored 0 to 100, on -44,690.7% operating margins and -61.8% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Cardio Diagnostics Holdings (CDIO) a high-quality business?+

Cardio Diagnostics Holdings scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -44,690.7% operating margin and a -61.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Cardio Diagnostics Holdings's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CDIO's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Cardio Diagnostics Holdings scores well and where it falls behind.

What is Cardio Diagnostics Holdings's return on invested capital (ROIC)?+

Cardio Diagnostics Holdings earns about -61.8% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CDIO's margins and growth on this scorecard to judge durability.

How profitable is Cardio Diagnostics Holdings?+

Cardio Diagnostics Holdings runs an operating margin of about -44,690.7% and a net margin of about -44,771.8%. Revenue has grown at roughly 101.4% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 7 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 8 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with CDIO

CompareIntrinsic value
ADTXAditxt Inc.
$0.00+33.33%20
NTRRNeutra Corp
$0.00+0.00%40
SKVISkinvisible Inc.
$0.16+0.00%0
GNLXGenelux Corp.
$1.96+2.08%10
JUNSJupiter Neurosciences Inc.
$2.46+1.23%10
SNTISenti Biosciences Inc.
$0.18-0.79%0
ASBPAspire Biopharma Holdings Inc.
$7.27-0.41%20
BDPTBioadaptives Inc.
$0.00-5.88%25

Spot a number that looks wrong? Check it in CDIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CDIO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.